Carestream Health and Bruker have entered into an agreement for Bruker to purchase the preclinical in-vivo imaging equipment product portfolio and related assets from Carestream's Molecular Imaging business. Financial terms of the agreement are not being disclosed.
As part of the transaction, the majority of Carestream employees involved in the preclinical in-vivo imaging business will be offered the opportunity to join Bruker. It is anticipated that the transaction will close in the next several weeks.
Carestream will retain the remaining assets of its Molecular Imaging business, including its life science X-ray film product lines and its Gel Logic and Image Station in-vitro imaging equipment product portfolio.
Carestream will continue operating its life science X-ray film business, and will continue to support its in-vitro product customers with service and parts.
New production of its Gel Logic and Image Station in-vitro products will be discontinued.
Dr. Werner Maas, President of Bruker BioSpin Corporation, commented: "We are excited about adding Carestream's in-vivo imaging systems to our preclinical imaging product portfolio. We believe that Carestream's optical molecular imaging product line will complement our other preclinical solutions, presently consisting of magnetic resonance imaging (MRI), magnetic particle imaging (MPI) and X-ray micro computed tomography (microCT). We also welcome the talented Carestream in-vivo employees to Bruker, and look forward to their contributions."